Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors (abst - 2004)http://www.ncbi.nlm.nih.gov/pubmed/15556131
Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity (abst – 2007)http://www.ncbi.nlm.nih.gov/pubmed/18038967
Pharmacological characterization of AM1710, a putative cannabinoid CB(2) agonist from the cannabilactone class: Antinociception without central nervous system side-effects (full – 2011) http://www.ncbi.nlm.nih.gov/pmc/arti...ihms280008.pdf
The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB2 receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy (full – 2012)http://www.molecularpain.com/content/8/1/71
Intrathecal cannabilactone CB(2)R agonist, AM1710, controls pathological pain and restores basal cytokine levels (full– 2012)http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3603341/
Prophylactic cannabinoid administration blocks the development of paclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug delivery (full – 2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3998744/
2012 Division of Medicinal Chemistry Award Address: Trekking the Cannabinoid Road: A Personal Perspective (full– 2014)http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4064474/
Chronic Cannabinoid Receptor 2 Activation Reverses Paclitaxel Neuropathy Without Tolerance or Cannabinoid Receptor 1-Dependent Withdrawal (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/24853387
Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity (abst – 2007)http://www.ncbi.nlm.nih.gov/pubmed/18038967
Pharmacological characterization of AM1710, a putative cannabinoid CB(2) agonist from the cannabilactone class: Antinociception without central nervous system side-effects (full – 2011) http://www.ncbi.nlm.nih.gov/pmc/arti...ihms280008.pdf
The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB2 receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy (full – 2012)http://www.molecularpain.com/content/8/1/71
Intrathecal cannabilactone CB(2)R agonist, AM1710, controls pathological pain and restores basal cytokine levels (full– 2012)http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3603341/
Prophylactic cannabinoid administration blocks the development of paclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug delivery (full – 2014) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3998744/
2012 Division of Medicinal Chemistry Award Address: Trekking the Cannabinoid Road: A Personal Perspective (full– 2014)http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4064474/
Chronic Cannabinoid Receptor 2 Activation Reverses Paclitaxel Neuropathy Without Tolerance or Cannabinoid Receptor 1-Dependent Withdrawal (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/24853387